Galapagos, BioFocus DPI, Eli Lilly, IonGate BioSciences, Sigma-Aldrich, Nanoco, Genetix Group | GenomeWeb
BioFocus DPI, Lilly Expand Hormone Receptor Discovery Agreement 
 
Galapagos announced this week that its service division BioFocus DPI has extended its drug discovery agreement with Eli Lilly until the end of 2008.
 
Under the terms of the agreement, BioFocus DPI will screen certain compounds as provided by Lilly against certain selected assays in quarterly screening campaigns to identify active compounds and provide selectivity information for Lilly’s nuclear hormone receptor research program.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.